Fundz

Contineum Therapeutics

San Diego, California, United States · Biopharma, Biotechnology, Health Care

Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications. The company has a pipeline of internally-developed programs to address multiple NI&I disorders, primarily targeting biological pathways associated with specific clinical impairments. Contine

Key facts

Headquarters
San Diego, California, United States
Employees
Unknown
Industries
Biopharma, Biotechnology, Health Care
Status
Public (CTNM)
Website
www.contineum-tx.com
LinkedIn
Company page

Recent activity at Contineum Therapeutics

  • : SEC 8-K (8.01): On September 14, 2026, Contineum Therapeutics, Inc. announced the results of the MOONLIGHT-1 Phase 2 clinical trial for JNJ-5120/PIPE-307 targeting major depressive disorder. The trial assessed the drug's efficacy, safety, and tolerability in adult participants. This drug is being developed by Johnson & Johnson under a global license and development agreement with Contineum, which is a significant collaboration for both companies in the mental health therapeutic area. The press release detailing the trial outcomes is attached as Exhibit 99.1.
  • : SEC 8-K (7.01): On July 13, 2026, Contineum Therapeutics, Inc. updated its corporate presentation to include important business and strategic updates, which is significant for stakeholders. The updated presentation, available as Exhibit 99.1, is intended to keep investors informed about the company's direction and will be regularly updated on the company's website. This move indicates the company's commitment to transparent communication, although it plans to streamline such updates by not filing a Form 8-K for each change. The event date of this update is crucial as it reflects the company's current strategies and potential impacts on its market position.
  • : SEC 8-K (8.01): On April 30, 2026, the Company announced topline data from its Phase 1b Trial of PIPE-791 in Chronic Pain, which primarily assessed the safety and tolerability of the treatment. The trial involved 43 patients with chronic osteoarthritic pain and chronic low back pain participating in a 4-week study designed to measure pain relief and adverse events. The trial found that PIPE-791 had a favorable AE profile, with mild to moderate treatment-emergent adverse events such as headache and fatigue reported, and improvements in pain intensity scores were observed compared to a placebo. This announcement highlights the company's progress in pain management research and potential implications for future treatments in the chronic pain sector, particularly as it reveals promising efficacy results that could influence market opportunities.
  • : SEC 8-K (7.01): On July 13, 2026, Contineum Therapeutics, Inc. updated its corporate presentation to reflect significant business and strategic updates. The updated presentation outlines recent developments and future plans which may influence stakeholder perceptions and investments. The presentation is attached as Exhibit 99.1 to the filing and will also be available on the company's website, indicating an ongoing effort to keep investors informed and engaged with the company's strategic direction. This update is crucial for stakeholders looking to assess the company's current positioning and future trajectory.
  • : SEC 8-K (8.01): On March 5, 2026, the Company entered into Amendment No. 1 to the Sales Agreement with Leerink Partners LLC, effectively increasing the aggregate offering price from $75,000,000 to $100,000,000 for shares of the Company’s Class A common stock. This Amendment updates previous terms under the Sales Agreement established on May 14, 2025, and includes a new ATM Prospectus Supplement that supersedes the earlier one. Notably, there is a lock-up period until March 11, 2026, during which no sales of ATM Shares will occur. Leerink Partners will facilitate sales classified as 'at the market offerings' under various approved methods, including through the Nasdaq Global Select Market. This amendment is significant as it expands the capital-raising potential for the Company while adhering to regulatory conditions.
  • : SEC 8-K (5.02): On January 23, 2026, the Board of Directors of Contineum Therapeutics, Inc. approved the 2026 Employment Inducement Equity Incentive Plan. This plan allows awards solely to eligible individuals under Nasdaq rules, and it reserves 750,000 shares of Class A common stock for issuance. Unlike the prior 2024 plan, it prohibits the issuance of incentive stock options. The approval of the plan was made without stockholder consent, adhering to Nasdaq Listing Rules, specifically Rule 5635(c)(4). This initiative is aimed at enticing new employees, ensuring that grants are considered as inducements for joining the company, potentially impacting future hiring strategies significantly.
  • : SEC 8-K (5.02): On January 23, 2026, the Board of Directors of Contineum Therapeutics, Inc. approved the 2026 Employment Inducement Equity Incentive Plan. This new plan shares similar terms with the 2024 Equity Incentive Plan, but prohibits the issuance of incentive stock options. The plan is specifically designed for eligible recipients in accordance with Nasdaq rules and was adopted without stockholder approval under Rule 5635(c)(4) of the Nasdaq Listing Rules. Initially, the Board has reserved 750,000 shares for this purpose, reflecting a strategic move to enhance talent acquisition and retention within the company.
  • : SEC 8-K (1.01): On December 11, 2025, Contineum Therapeutics, Inc. entered into an Underwriting Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC for the sale of 7,346,938 shares of its Class A common stock at a public price of $12.25 per share. The Underwriters purchased the shares at $11.515 per share, estimating net proceeds of approximately $84.2 million from the Offering, which closed on December 15, 2025. Under the agreement, the Underwriters also received an option to purchase an additional 1,102,040 shares within 30 days. This transaction was made under the Company's shelf registration statement and includes customary terms and indemnification obligations.
  • : SEC 8-K (8.01): On December 8, 2025, the Company submitted details of its global Phase 2 clinical trial of PIPE-791 for idiopathic pulmonary fibrosis (IPF) to the ClinicalTrials.gov Protocol Registration and Results System. This trial is a 26-week, international, randomized, double-blind, placebo-controlled study that plans to enroll approximately 324 subjects globally, assessing safety, tolerability, and efficacy of the treatment. The trial is expected to be completed in June 2028. The submission follows regulatory engagement based on the Company’s earlier draft protocol and completed Phase 1 trials, indicating a significant step forward in their clinical development strategy for PIPE-791.
  • : SEC 8-K (8.01): On November 20, 2025, Contineum Therapeutics, Inc. issued a press release providing topline data from its Phase 2 PIPE-307 VISTA trial for the treatment of relapsing-remitting multiple sclerosis. This trial is significant as it contributes to the understanding and potential treatment options for this condition. The press release, which is attached as Exhibit 99.1, details the interim results and their implications for future clinical development. This event is noteworthy for investors and stakeholders in the biopharmaceutical sector due to its potential impact on the company's market position and research initiatives.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Leadership

  • John Healy, General Counsel

Verified email and direct lines for Contineum Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Contineum Therapeutics in the news

Companies similar to Contineum Therapeutics

  • AnHeart Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
  • YS Biopharma · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
  • Innovent Biologics (Innovent) · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
  • Sino Biopharmaceutical · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
  • Jubilant Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics

About Contineum Therapeutics: questions and answers

What does Contineum Therapeutics do?

Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications. The company has a pipeline of internally-developed programs to address multiple NI&I disorders, primarily targeting biological pathways associated with specific clinical impairments. Contine

Where is Contineum Therapeutics headquartered?

Contineum Therapeutics is headquartered in San Diego, California, United States.

What is the latest news on Contineum Therapeutics?

On Nov 20, 2025, SEC 8-K (8.01): On September 14, 2026, Contineum Therapeutics, Inc. announced the results of the MOONLIGHT-1 Phase 2 clinical trial for JNJ-5120/PIPE-307 targeting major depressive disorder. The trial assessed the drug's efficacy, safety, and tolerability in adult participants. This drug is being de

Is Contineum Therapeutics a public company?

Yes. Contineum Therapeutics is publicly traded under the ticker CTNM.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Contineum Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.